 | Up a level |
Journal Article
Belada, David 
ORCID: 0000-0002-4981-6188, Georgiev, Pencho ORCID: 0000-0001-5677-6754, Dakhil, Shaker, Inhorn, Lowell F., Andorsky, David, Beck, J. Thaddeus, Quick, Donald, Pettengell, Ruth, Daly, Robert, Dean, James P., Pavlyuk, Mariya, Failloux, Nelly and Huebel, Kai
(2016).
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Future Oncol., 12 (15).
S. 1759 - 1769.
LONDON:
FUTURE MEDICINE LTD.
ISSN 1744-8301
Harrison, Claire N., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Zhou, Huafeng, Kiladjian, Jean -Jacques, Vannucchi, Alessandro M., Nangalia, Jyoti, Mead, Adam and Mesa, Ruben A.
(2016).
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Harrison, Claire N., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Zhou, Huafeng, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Nangalia, Jyoti, Mead, Adam and Mesa, Ruben A.
(2016).
Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Mesa, Ruben A., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Jourdan, Eric, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Cernohous, Paul, Nangalia, Jyoti, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Mead, Adam and Harrison, Claire N.
(2015).
Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
J. Clin. Oncol., 33 (18).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Mesa, Ruben A., Egyed, Miklos, Szoke, Anita, Suvorov, Aleksandr, Perkins, Andrew ORCID: 0000-0003-3644-7093, Mayer, Jiri, Ganly, Peter, Schouten, Harry C., Tosi, Patrizia, Farber, Charles Michael, Zachee, Pierre, Scheid, Christof, Dean, James P., Granston, Tanya, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Nangalia, Jyoti, Mead, Adam and Harrison, Claire N.
(2016).
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755